Drug Profile


Alternative Names: LFG-316; NOV-4

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator MorphoSys; Novartis
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Complement C5 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Choroiditis; Dry age-related macular degeneration; Panuveitis; Paroxysmal nocturnal haemoglobinuria; Thrombotic microangiopathy; Wet age-related macular degeneration

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 26 Aug 2016 Novartis Pharmaceuticals initiates a drug-drug interaction phase I trial in USA (unspecified route) (NCT02878616)
  • 18 Dec 2015 Phase-II clinical trials in Thrombotic microangiopathy (In children, In adolescents, In adults) in France (IV) (EudraCT2014-004972-49)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top